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2052Objectives: This study examined the outcomes of surgery for active prosthetic valve endocarditis in a recent
decade, with special interest in preoperative treatment and predictors for early and late events.
Methods: From 2000 to 2010, a cohort of 149 consecutive patients (mean age, 64 13.9 years; 72%were male)
underwent redo-surgery for prosthetic valve endocarditis and were reviewed regarding early (60 days) and late
(>60 days) events (death, reinfection, reoperation). Kaplan–Meier survival curves and Cox regression analysis
were used to investigate the impact of preoperative intervals and predictors for events, respectively.
Results: Preoperative status was critical (European System for Cardiac Operative Risk Evaluation>20%) in
121 patients (81.2%). Staphylococci were the most common infecting microorganisms (27.5%). The
median interval between onset of symptoms and diagnosis and between diagnosis and operation was 2 days
(interquartile range, 1-5) and 8 days (interquartile range, 2-23), respectively. Operative mortality (30 days)
was 12.8%. Mean follow-up was 4  2.9 years. In 53 patients, 47 early (24 deaths, 14 recurrences, 9 reopera-
tions) and 22 late events (11 deaths, 9 recurrences, 2 reoperations) occurred. Overall and event-free survivals at
10 years were 75%  3.8% and 64%  4.0%, respectively. Freedom from recurrent infection and reoperation
at 10 years were 81%  3.6% and 91%  2.6%, respectively. In multivariate Cox regression, mechanical
circulatory support, prolongation between onset of symptoms and diagnosis more than 30 days, and preoperative
presence of renal failure predicted early events, and double valve replacement predicted late events.
Conclusions: Cardiac and renal function, need for double valve replacement, and preoperative treatment
predicted outcomes. A prolonged interval in which patients were left untreated while symptomatic, but not
prolongation of preoperative antibiotic treatment, increased risk. (J Thorac Cardiovasc Surg 2014;148:2052-9)Prosthetic valve endocarditis (PVE), a severe complication of
heart valve surgery and themost severe form of infective endo-
carditis (IE), is associated with significant morbidity and mor-
tality.1-8 PVE accounts for 10% to 30% of all cases of IE
and occurs in 1% to 6% of patients with valve prostheses,
equally affecting mechanical and biological valves.3,9-11
Despite improvements in echocardiography, increasing
knowledge, and periodically reviewed multidisciplinary
guidelines, there are still difficulties in the diagnosis of
PVE, because the clinical presentation is rather atypical
and blood cultures and echocardiography results are
frequently negative.5,11 Although there is consensus that
surgery is required in complicated PVE (heart failure,
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The Journal of Thoracic and Cardiovascular Surfever, aggressive microorganisms, large vegetations),
there is an ongoing discussion about general therapeutic
strategies.4,5,11 For left-sided native valve IE, data from a
randomized study in 76 patients with severe valve disease
and large vegetations demonstrated a significant reduction
of the composite end point of death from any cause and
embolic events by early surgery versus conventional
treatment,12 but data regarding PVE are conflicting. Lalani
and colleagues13 recently showed that after adjustment for
differences in clinical characteristics and survival bias in
1025 patients with PVE, early valve replacement was not
associated with lower mortality compared with medical
therapy in the overall cohort.
Therefore, we reviewed our experience of surgery for
PVE during the most recent decade. With respect to death,
recurrent infection, and reoperation, early and late events
were analyzed and the impact of preoperative time delay
between onset of symptoms and diagnosis and between
diagnosis and operation was investigated. Furthermore,
we sought to identify independent predictors for early and
late events.
METHODS
Patients
With approval from our institutional Ethics Committee (EA1/032/13), we
performed a retrospective review of consecutive patients who underwentgery c November 2014
Abbreviations and Acronyms
IE ¼ infective endocarditis
IQR ¼ interquartile range
PVE ¼ prosthetic valve endocarditis
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Charite Campus Mitte, Berlin, between 2000 and 2010. We identified
149 patients (107 male, 42 female) with a mean age of 63.5  13.8 years
(range, 26-83). Among them, 65 (43.3%) presented with early and 84
(56.4%) presented with late PVE. The median time between first valvular
surgery and reoperation was 4.1 years (interquartile range [IQR], 0.3-5.9)
for all patients, 3 months (IQR, 1.7-6.7) for early PVE, and 4.9 years
(IQR, 2.9-9.9) for late PVE. Primary surgery was due to IE in 26 patients
(40.0%) and 15 patients (17.9%) with early and late PVE.
Definitions
Diagnosis of PVE was based on clinical findings (fever, inflammatory
syndromes), laboratory testing (blood cultures, leukocytosis, levels of
C-reactive protein and procalcitonin), results of transthoracic/transesopha-
geal echocardiography, and intraoperative findings.11,14 According to the
Guidelines of the European Society of Cardiology, PVE occurring within
1 year of primary valvular surgery was classified as early and beyond 1
year as late.11 Culture-negative endocarditis was present when no
microorganism could be identified, neither in serial blood cultures nor in
cultures from the explanted material despite the presence of characteristic
signs for endocarditis (vegetations, periprosthetic destructions, or pus).
Clinical variables were defined according to the terms of the Society of
Thoracic Surgeons National Cardiac Surgery Database. For perioperative
risk assessment, Society of Thoracic Surgeons and logistic European
System for Cardiac Operative Risk Evaluation scores were determined.15,16
PVE predispositions were classified following the criteria proposed by
Grinda and colleagues.17 Endocarditis was considered locally uncontrolled
when the infectious pathology extended beyond the prosthetic valve (ie,
destruction or purulent deformation of adjacent tissue, periprosthetic ab-
scesses, and fistulas into a cardiac chamber or pericardium). Concomitant
procedures were all surgical procedures performed to correct associated
noninfective cardiac diseases. Events were defined by death, recurrent
PVE, and reoperation. Prolonged hospital stays were classified as early if
they occurredwithin 60 days after surgery or late if they occurred thereafter.
Surgery and Postoperative Treatment
The most common indications for surgery were vegetations greater than
10 mm (n ¼ 109, 73.2%), locally uncontrolled infection (n ¼ 90, 60.4%),
and heart failure (n ¼ 65, 43.6%), which was caused by severe prosthetic
valve dysfunction (n ¼ 61) or fistulas (n ¼ 4). More than 1 indication for
surgery was present in 78 patients (52.3%).
All operations were performed through a median sternotomy using an
oscillating saw. Cardiopulmonary bypass, installed via cannulation of the
distal ascending aorta, the aortic arch or femoral artery, and the right
atrium or femoral vein, was used with systemic normothermia or mild
hypothermia (32C) if a patent thoracic artery bypass was present.
Myocardial protection was achieved with intermittent antegrade blood
cardioplegia. Previously implanted prostheses were removed in total, and
abscesses and fistulas were thoroughly debrided. The remaining tissue
was disinfected using povidone-iodine solution. In the presence of large
abscess cavities, fistulas, or tissue defects, a pericardial (autologous, bovine
or equine) patch repair was performed. The choice for the new prosthesis
was at the discretion of the surgeon. Concomitant procedures, if needed,
were performed according to standard techniques. Infected intravascular
catheters were removed before surgery.The Journal of Thoracic and CarAll patients underwent intravenous antibiotic/antimycotic treatment for
at least 6 weeks postoperatively. Antibiotic regimen was directed by
microbiological findings and based on guidelines.11 In the case of
culture-negative PVE, an empirical, broad-range, antibiotic treatment was
initiated, usually consisting of vancomycin, rifampicin, and gentamycin.
Follow-up
Follow-up was obtained by telephone interviews and mail
questionnaire. Complications were confirmed by contact with the patient’s
cardiologist or family physician. In case of rehospitalizations, copies of the
medical reports were obtained.
Statistical Analysis
Categoric variables are reported as absolute and relative frequencies.
For continuous data, means and standard deviations or medians and
interquartile ranges were calculated. For comparison of microbiological
findings in patients presenting with early and late PVE, the Fisher
chi-square test was used. Overall and event-free survival, and freedom
from recurrence and reoperation were analyzed using Kaplan–Meier
curves and log-rank test. A Cox regression analysis was used to identify
predictors for early and late events. First, a univariate approach evaluating
all possible risk factors was applied, followed by a multiple Cox regression
(backward elimination; likelihood ratio) of all significant variables.
Aikaike’s information criterion was used to assess the goodness of fit.
The assumption of proportional hazard was checked. All the statistical
analyses were performed using SPSS Statistics 19 for Windows
(SPSS Inc, Chicago, Ill) and supervised by an independent statistician
(K.-D.W.). Because of the exploratory nature of the study, no adjustment
for multiple testing was carried out.
RESULTS
Baseline Characteristics
Preoperative status was critical in a significant number of
patients (Table 1): sepsis (n¼ 23), shock (n¼ 14), acute renal
failure (n ¼ 17), and the necessity of mechanical ventilation
(n ¼ 17) and pharmacologic circulatory support (n ¼ 19).
Accordingly, logistic European System for CardiacOperative
Risk Evaluation was greater than 20% in 121 patients
(81.2%). A total of 49 patients (32.9%) sustained 1 or multi-
ple embolic complications involving 1 ormore systems: brain
including retina (n ¼ 28), mesenteric circulation including
spleen (n ¼ 14), upper or lower limbs (n ¼ 11), kidneys
(n¼ 6), and coronary arteries (n¼ 5). Extracardiac infection
was present in 31 patients (20.8%), including pneumonia or
pulmonic abscess (n ¼ 7), skin or soft tissue infection
(n ¼ 6), urogenital infection (n ¼ 5), spondylodiscitis and
nonsternal osteomyelitis (n ¼ 5), intra-abdominal infection
or abscess (n¼ 3), surgical site infection after primary cardiac
surgery (n¼ 3), and infected intravascular catheters (n¼ 2).
Oneormore extracardiac predispositions for IEwere found in
51 patients (39.6%), including diabetes (n¼ 38), intravenous
drug abuse (n ¼ 9), alcoholism (n ¼ 6), corticotherapy
(n¼ 4), chemotherapy (n¼ 3), leukemia (n¼ 1), and chronic
hemodialysis (n ¼ 4).
Preoperative Time Intervals
Median time intervals between onset of symptoms
and diagnosis and between diagnosis and operation werediovascular Surgery c Volume 148, Number 5 2053
TABLE 1. Baseline characteristics and operative data
Parameter n (%) Mean ± SD
Age (y) 63.5  13.85
Age>70 y 58 (38.9)
Male gender 107 (71.8)
BSA (m2) 1.9  0.21
NYHA class I-II 65 (43.6)
NYHA class III-IV 84 (56.4)
LVEF 0.51  0.12
LVEF<0.40 21 (14.1)
STS score 17.9  10.82
euroSCORE 41.5  24.18
euroSCORE>20% 121 (81.2)
euroSCORE>40% 66 (44.3)
Early PVE 65 (43.6)
Late PVE 84 (56.4)
Sepsis 23 (15.2)
Shock 14 (9.4)
Cardiogenic 6 (4.0)
Septic 8 (5.4)
Preoperative ventilatory support 17 (11.4)
Preoperative circulatory support
(catecholamines)
19 (12.8)
Preoperative renal failure 17 (11.4)
Chronic hemodialysis 4 (2.7)
Preoperative neurologic deficits 36 (24.2)
Previous embolic events 49 (32.9)
Isolated 32 (21.5)
Multiple 17 (11.4)
Pulmonary hypertension 22 (14.8)
Previous myocardial infarction 9 (6.0)
Diabetes 38 (25.5)
COPD 29 (25.5)
Arterial hypertension 67 (45.0)
Operative priority
Emergency 47 (31.5)
Urgent 55 (36.9)
Elective 47 (31.5)
Procedural figures
Operation time (min) 260  88.3
CPB time (min) 149  62.4
ACC time (min) 112  44.3
Surgical procedures
Aortic valve surgery 92 (61.7)
Mechanical prosthesis 11 (12.0)
Bioprosthesis 80 (87.0)
Autograft (Ross procedure) 5 (5.4)
Mitral valve surgery 42 (28.2)
Mechanical prosthesis 6 (14.3)
Bioprosthesis 36 (85.7)
Double valve surgery 15 (10.1)
Mechanical prosthesis 2 (13.3)
Bioprosthesis 13 (86.7)
Concomitant procedures 7 (4.7)
Mitral valve repair 1 (14.3)
Tricuspid valve repair 1 (14.3)
CABG 5 (71.4)
(Continued)
TABLE 1. Continued
Parameter n (%) Mean ± SD
Mechanical circulatory support 14 (9.4)
IABP 11 (7.4)
LVAD 1 (0.7)
RVAD 2 (1.3)
ACC, Aortic crossclamp time; BSA, body surface area;CABG, coronary artery bypass
grafting; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary
bypass time; euroSCORE, European System for Cardiac Operative Risk Evaluation;
IABP, intra-aortic balloon pump; LVAD, left ventricular assist device; LVEF, left ven-
tricular ejection fraction; PVE, prosthetic valve endocarditis; RVAD, right ventricular
assist device; SD, standard deviation; NYHA, New York Heart Association; STS, The
Society of Thoracic Surgeons.
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D2 days (interquartile range 1-5) and 8 days (2-23), respec-
tively. The diagnosis of PVE was established within 2
weeks after the onset of symptoms in 130 patients
(87.2%) and later in 19 patients (12.8%). Surgery was
performed within 2 weeks after diagnosis of PVE in 98 pa-
tients (65.8%) and later in 51 patients (34.2%). The interval
between onset of symptoms and diagnosis was more than 30
days in 8 patients, and the interval between diagnosis and
operation was more than 30 days in 23 patients.Microbiological Findings
The results of blood and valve cultures are listed in
Table 2. Staphylococci were the most common infecting
microorganisms, in both early and late PVE. In late PVE,
Streptococci and Enterococcus faecalis were frequently
present. Problematic germs (Staphylococci, gram-negative
bacteria, fungi, multiresistent organisms) caused uncon-
trolled infection in 52 patients (34.9%). Despite repeated
blood cultures, intraoperative swabs, examination of the
explanted valves, serodiagnostics, and techniques of
cellular microbiology, endocarditis was culture-negative
in 35.6% of patients.Operation and Perioperative Course
Previous valvular surgery comprised 6 mitral valve
reconstructions and 164 aortic, mitral, or double valve
replacements, including 113 bioprostheses, 45 mechanical
valves, and 6 Ross procedures. The recent operations data
are summarized in Table 1. Only 31.5% were elective pro-
cedures. In the majority of patients (86.6%), bioprostheses
were used, in aortic position predominantly stentless valves
(91.4%). The implantation technique of stentless aortic
valve prostheses was subcoronary in 51 patients, inclusion
cylinder in 33 patients, and root replacement in 9 patients.
For reconstruction of perivalvular tissue defects, pericardial
patch repair was performed in 12 patients.
Five patients died intraoperatively, and 14 patients
died within 30 days after surgery, resulting in an overall
operative mortality (30 d) of 12.8%. In 4 moribund pa-
tients, intraoperative death occurred because of unfavorable
cardiac or septic shock even before cardiopulmonarygery c November 2014
TABLE 2. Microbiological findings
Microorganism
Total
population
n ¼ 149
Early
PVE
n ¼ 65
Late
PVE
n ¼ 84
Staphylococcus species, n (%) 41 (27.5) 23 (35.4) 18 (21.4)*
Staphylococcus aureus (NMR) (n) 16 6 10
MRSA (n) 3 2 1
Staphylococcus epidermidis (n) 16 10 6
Staphylococcus hominis (n) 5 5 —
Staphylococcus lugdunensis (n) 1 — 1
Streptococcus species, n (%) 24 (16.1) 8 (12.3) 16 (19.0)
Streptococcus viridans (n) 11 4 7
Streptococcus agalactiae (n) 1 — 1
Streptococcus bovis (n) 6 2 4
Streptococcus pyogenes (n) 5 1 4
Streptococcus dysgalactiae (n) 1 1 —
Enterococcus faecalis, n (%) 20 (13.4) 4 (6.2) 16 (19.0)y
Enterobacter cloacae, n (%) 1 (0.7) — 1 (1.2)
Pseudomonas aeruginosa, n (%) 2 (1.3) 1 (1.5) 1 (1.2)
Escherichia coli, n (%) 1 (0.7) — 1 (1.2)
Klebsiella pneumoniae, n (%) 1 (0.7) — 1 (1.2)
ESBL-producing Gram-negative
pathogens, n (%)
3 (2.0) 2 (3.1) 1 (1.2)
Corynebacterium jeikeium, n (%) 2 (1.3) 1 (1.5) 1 (1.2)
Candida species, n (%) 3 (2.0) — 3 (3.6)
Multiple microorganisms, n (%) 4 (2.7) 1 (1.5) 3 (3.6)
Culture-negative endocarditis, n (%) 53 (35.6) 25 (38.5) 28 (33.3)
ESBL, Extended-spectrum beta lactamase; MRSA, methicillin-resistant staphylo-
coccus aureus; NMR, non–methicillin-resistant; PVE, prosthetic valve endocarditis.
*P ¼ .059. yP ¼ .022 (chi-square test early vs late PVE).
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Dbypass was installed (3 patients) and uncontrollable
bleeding (1 patient). Themain causes of postoperative death
were multiple organ failure (n ¼ 7), refractory cardiac
failure (n ¼ 5), and uncontrolled sepsis (n ¼ 2). Mean
intensive care unit and hospital stays were 11.0  20.8
days and 37.3  30.2 days, respectively. Perioperative
morbidity was significant, and 117 patients (78.5%) expe-
rienced at least 1 disease or surgery-related complication.
These included reoperation (n ¼ 9) due to recurrent PVE
(n ¼ 14), acute renal failure requiring hemodialysis
(n ¼ 38), pulmonary failure requiring prolonged mechani-
cal ventilation (n ¼ 30), atrial fibrillation (n ¼ 30),
nosocomial pneumonia (n ¼ 14), complete heart block
requiring permanent pacemaker implantation (n ¼ 12),
transient delirium (n ¼ 8), and permanent (n ¼ 6) or
transient (n ¼ 4) neurologic events. Reexploration for
bleeding or pericardial tamponade was necessary in 14
patients. Surgical site infection occurred in 3 patients.
Event-Related Outcome
Length of follow-up was 4  2.9 years (range, 0-10.3
years) and 96% complete (6 patients were lost). According
to the definitions given earlier, 69 events (47 early, 22 late)
occurred in 53 patients, including 35 deaths (24 early, 11
late), 23 recurrences (14 early, 9 late), and 11 reoperationsThe Journal of Thoracic and Car(9 early, 2 late). The causes of deaths were cardiac in 22 pa-
tients (intraoperative death in 5, heart failure in 7, recurrent
endocarditis in 5, sudden cardiac death in 3, myocardial
infarction in 2), noncardiac in 10 patients (multiple organ
failure in 7, intractable sepsis in 2, coagulopathy in 1),
and unknown in 5 patients. Recurrent endocarditis (18 cases
occurred within 1 year) was treated with antibiotics alone in
12 patients (3 deaths) and by redo surgery in 11 patients
(2 deaths). The offending microorganism was the same as
in the first infection in 10 patients, different in 4 patients,
and culture-negative in 9 patients. All reoperations were
performed for recurrent endocarditis. Figure 1 shows the
actuarial results for these events.
Association Between Preoperative Treatment and
Occurrence of Events
Events occurred more frequently when PVE was diag-
nosed more than 30 days after the onset of symptoms,
whereas surgery more than 30 days after diagnosis did not
influence the event rate (Figure 2). It has to be stressed
that no patient who experienced more than a 30-day delay
between onset of symptoms and diagnosis was receiving
medical treatment for PVE, whereas almost all patients
(n ¼ 21, 91.3%) who underwent operation more than 30
days after PVE was detected were treated with antibiotics.
In the latter group, there was no clear indication for surgery
at the time of diagnosis. However, during the course of
medical treatment, persistent infection characterized by
increasing or persistent vegetations (14 patients, 60.9%)
and locally uncontrolled infection (9 patients, 39.1%)
evolved and eventually required surgery.
Risk Factors for Early and Late Events
According to Cox regression analysis, the risk factors for
early and late events are shown in Table 3. Because
mechanical circulatory support, prolongation between
onset of symptoms and diagnosis more than 30 days, and
preoperative presence of renal failure are independent risk
factors for early events, we found that advanced heart
failure, untreated PVE, and secondary organ damage are
significant predictors for early outcome. On the other
hand, the long-term outcome is determined by extensive
valvular involvement, because patients requiring double
valve replacement were at higher risk for late events.
For other variables, in particular age, gender, causative
microorganism, early or late PVE, locally uncontrolled
infection, aortic crossclamp time, and type of prosthesis,
we were unable to detect any association with increased
risk.
Comment
This study presents the results of surgery for PVE in the
most recent decade. The outcome was limited by death,
recurrent endocarditis, and need for reoperation occurringdiovascular Surgery c Volume 148, Number 5 2055
FIGURE 1. Outcome after surgery for PVE for all patients. Kaplan–Meier curves for overall and event-free survival and for freedom from recurrent PVE
and reoperation are depicted.
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with the early postoperative period, the incidence of such
events was less than half at long-term follow-up
(>60 days, up to 10 years). Several risk factors could be
identified: need for mechanical circulatory support,
prolongation between onset of symptoms and diagnosis
more than 30 days, and preoperative presence of renal
failure as predictors for early events and need for double
valve replacement as a predictor for late events.
Predictors for Early Events
The 3.8-fold increase of risk of early events by need for
mechanical circulatory support reflects the impact of severe2056 The Journal of Thoracic and Cardiovascular Surcardiac failure, which is known as an important risk factor
not only in patients undergoing surgery for prosthetic or
native valve IE,3,5,6,13,18-20 but also for cardiac surgery in
general.16 Among other independent risk factors, such as
emergency operation, preoperative catecholamines, mitral
valve replacement, and age, mechanical circulatory support
was previously shown to be the strongest predictor for early
mortality (<30 days) after surgery for PVE.20
Although the diagnosis of PVE was established within 2
weeks after the presence of symptoms in the majority of
our patients, prolongation of this interval more than
30 days—correlating with duration of untreated PVE
more than 30 days—was associated with a similar increasegery c November 2014
FIGURE 2. Association between preoperative treatment and events. Kaplan–Meier curves show comparison of event rates according to preoperative
intervals. Almost all patients were receiving medical treatment with antibiotics between diagnosis and surgery, whereas no patient was between onset of
symptoms and diagnosis.
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PVE more than 30 days until strong indications for surgery
were present (interval between diagnosis and operation>30
days) did not add any risk. This finding is in line with
recently published results of the International CollaborationTABLE 3. Risk factors for early and late events
HR 95% CI P
Early events (60 d)
Univariate Cox regression
Mechanical circulatory support 4.931 2.288-10.630 <.001
NYHA class IV 4.084 1.818-9.174 .001
Preoperative ventilatory support 3.124 1.514-6.445 .001
Shock 3.104 1.422-6.779 .003
Emergency operation 3.084 1.290-7.313 .001
Interval symptoms-diagnosis>30 d 3.059 1.190-7.865 .015
Preoperative renal failure 3.005 1.535-5.881 .001
Preoperative circulatory support 2.804 1.360-5.779 .004
LVEF<0.40 2.727 1.174-4.394 .012
Preoperative lactate<2 mmol/L 2.400 1.185-4.861 .012
euroSCORE>40% 1.885 1.002-3.591 .050
CPB time 1.005 1.001-1.009 .026
Multivariate Cox regression
Mechanical circulatory support 3.823 1.742-8.389 .001
Interval symptoms-diagnosis>30 d 3.130 1.202-8.149 .019
Preoperative renal failure 2.322 1.113-4.845 .025
Late events (>60 d)
Univariate Cox regression
Interval symptoms, surgery>90 d 4.391 1.016-19.591 .034
Double valve replacement 4.005 1.368-11.730 .006
Multivariate Cox regression
Double valve replacement 4.446 1.568-12.608 .005
CI, Confidence interval; CPB, cardiopulmonary bypass; euroSCORE, European
System for Cardiac Operative Risk Evaluation; HR, hazard ratio; LVEF, left
ventricular ejection fraction; NYHA, New York Heart Association.
The Journal of Thoracic and Caron Endocarditis–Prospective Cohort Study, a prospective,
multinational, observational study in 1025 patients with
PVE demonstrating that early surgery (median time from
admission to surgery 8 days) was not associated with lower
mortality compared with medical therapy unless clear
indications for surgery, such as valve regurgitation,
vegetation, and dehiscence or paravalvular abscess/fistula,
were present.13 However, Lalani and colleagues13 did not
evaluate the duration of preoperatively untreated PVE and
the potential benefit of earlier compared with later surgery,
which may influence the outcome. Furthermore, they only
analyzed outcome regarding mortality but did not report
results with respect to recurrence of PVE and reoperation.
The diagnosis of PVE is difficult because the clinical pre-
sentation is rather atypical and the results of blood cultures
and echocardiography are more frequently negative.5 Even
transesophageal echocardiography, which is mandatory in
the assessment of PVE, initially may be falsely negative in
true PVE.5 Considering these results (Figure 2), it has to
be concluded that initiating antibiotic treatment in the case
of clinical suspicion of PVE makes more sense than merely
waiting until diagnosis is confirmed by repeated echocardi-
ography. Medical treatment seems to be appropriate as long
as clear indications for surgery (heart failure, uncontrolled
infection, prevention of embolism) are missing.
In this study, preoperative renal failure evolved as
the third independent risk factor for early events. In
the context of IE, renal dysfunction can be regarded as
end-organ damage due to congestive heart failure and low
cardiac output, renal embolization, or immune complex
glomerulonephritis. Consequently, renal complications
occur in 5% to 10% of patients with IE and renal failure
was demonstrated to be a significant predictor of earlydiovascular Surgery c Volume 148, Number 5 2057
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prosthetic IE.6,20-23
Predictors for Late Events
We found double valve replacement as an independent
predictor for late events. Because all patients undergoing
double valve surgery presented with IE affecting both
valves, this result emphasizes the importance of extensive
valvular infection. Accordingly, we have previously found
that apart from older age and preoperative renal failure,
concomitant mitral valve surgery due to endocarditis was
an independent predictor of late death after surgery for
aortic valve IE.23 There are few reports analyzing predictors
for long-term outcome after surgery for PVE. In contrast to
our results, available data from studies on surgery for IE
could not demonstrate double valve replacement as a risk
factor for long-term outcome.21,24 However, within these
cohorts, (1) only 30% to 43% of patients presented with
PVE and (2) information on how many double valve
procedures were performed for double valve infection was
not given.21,24
Prognostic Implications Considering Survival,
Recurrent Infection, and Reoperation
Consistent with recent reports from Sweden and the
Cleveland Clinic, reporting an early mortality (30 days)
after surgery for PVE of 14% and 13%, respectively,7,8
our study found a decrease in operative mortality
compared with the rates in previous eras.25 Nevertheless,
mortality remains a significant issue and can reach 20%
to 30% if preoperative status is critically limited or PVE
is more complicated.4-6,9,20 Several factors have been
associated with increased mortality, of which complicated
PVE and staphylococcal infections are the most powerful
markers.5 As in our patients, staphylococci are the
most common causative microorganisms for PVE
today.4,6-8,13,20 Overall survival at 5 years was 76.7% in
this study, which is similar to that in recent reports from
other groups.7,8 Considering that an increasing amount of
patients with IE have PVE, these long-term results are
promising because they do not significantly differ from
native IE.7,8 In contrast to other reports,7,8,20 survival
remained stable beyond 5 years in our patients and was
approximately 75% at 10 years.
In regard to the long-term prognosis of PVE, event-free
survival, considering at least the incidence of reinfection
and reoperation in addition to mortality, is more realistic
(Figure 1). The majority of such events occurred within
the first year after operation, confirming observations
from Musci and colleagues.20 The rate of reinfections and
reoperations after surgery for PVE has not been frequently
reported. At 10 years, Musci and colleagues20 report
freedom from reoperation due to reinfection of 85.8%
and 92.1% after surgery for early and late PVE,2058 The Journal of Thoracic and Cardiovascular Surrespectively. Comparably, in this study freedom from
reoperation, all redo procedures were due to recurrent
endocarditis, was 91% at 10 years.
Obviously, not all cases of recurrent endocarditis require
reoperation, although the earlier reinfection occurs the more
frequently repeat surgery will be necessary. Thus, 52% of
our patients who presented with reinfection, but missed
any clear indication for surgery, were successfully treated
medically. For the long-term perspective, however, not
only late reinfection or de novo infection but also prosthetic
valve dysfunction, in particular structural deterioration of
bioprostheses, and other reasons have to be considered
indications for reoperation.24
The optimal substitute to be used for replacement of an
infected valvular prosthesis is still a matter of debate.
Studies comparing mechanical and biological prostheses
for IE,22 homografts and conventional prostheses for aortic
IE,26 or homografts and composite prostheses for aortic
PVE27 demonstrated that operative mortality, early and
long-term survival, and risk of reinfection and reoperation
were similar and therefore independent of the type of
substitute implanted. In particular, aortic valve homografts
are believed to be ideally suited to treat PVEwith aortic root
abscess.17,20,28,29 However, for patients requiring second
reoperation for reinfection, 61.1% presented with aortic
root abscess at first reoperation, which was treated by
homograft aortic root replacement.20 Moreover, although
Musci and colleagues20 used homograft aortic root replace-
ment in 38.4% of their patients, the reoperation rate is iden-
tical to that found in this study, in which stentless
bioprostheses were predominantly used for aortic valve
replacement. In general, the benefit of surgery seems to
be more related to the ability to extirpate all infected tissue
than to the prosthesis used for replacement itself.24
Study Limitations
Because of the retrospective nature of the present study, it
has limitations because no patient was assigned to specific
treatment. The conclusion that preoperative treatment
predicts outcomes is limited by the small patient number.
Furthermore, it reports results from a single surgical center,
and although this is part of a huge university hospital,
patients have been referred from different hospitals. Also,
no solely medically treated cohort was available whose
outcome could be compared with this surgical cohort.
However, all patients were included consecutively during
the most recent decade and followed for a sufficiently
long time period.
CONCLUSIONS
Surgery for PVE is frequently required and remains
associated with a significant risk for not only death but
also reinfection and reoperation. Cardiac and renal
function, the need for double valve replacement, andgery c November 2014
Grubitzsch et al Acquired Cardiovascular Disease
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C
Dpreoperative treatment predicted outcomes. The risk, in
particular for early events, increased significantly if the
preoperative interval in which patients were symptomatic
but not treated exceeded 30 days, whereas preoperative
medical treatment with antibiotics—as long as no clear
indication for surgery was present—for more than 30 days
was not associated with increased risk.
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